Clinical Trial Update: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors [Phase 1]

View source ↗

Summary

Phase I clinical trial update evaluating dose, pharmacokinetics, and safety of Lutetium-177-edotreotide therapy in pediatric participants with somatostatin rece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumor
• Gastrointestinal Stromal Tumor
• Lymphoma
• Neuroendocrine Tumor
• Peripheral Primitive Neuroectodermal Tumor
• Rhabdomyosarcoma

Drugs mentioned

• Lutetium-177-edotreotide (Lutetium-177 edotreotide)

Snippet

Sponsor: ITM Solucin GmbH | Conditions: Somatostatin Receptor Positive, NETs | Phase 1 | Status: RECRUITING